November 17, 2016 - By Darrin Black · 0 Comments
The stock of Tonix Pharmaceuticals (NASDAQ:TNXP) registered an increase of 10.81% in short interest. TNXP’s total short interest was 828,400 shares in November as published by FINRA. Its up 10.81% from 747,600 shares, reported previously. With 2.43 million shares average volume, it will take short sellers 0 days to cover their TNXP’s short positions. The short interest to Tonix Pharmaceuticals’s float is 3.73%. About 311,465 shares traded hands. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has declined 85.05% since April 15, 2016 and is downtrending. It has underperformed by 89.68% the S&P500.
Tonix Pharmaceuticals Holding Corp. (Tonix), incorporated on November 16, 2007, is a clinical-stage pharmaceutical company. The Company’s drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). The Firm is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications.
Another recent and important Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) news was published by Businessfinancenews.com which published an article titled: “Tonix Pharmaceuticals Holding Corp Ready to Clinch Share From PTSD Market” on June 02, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black